Itoco Inc. (ITMC)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Itoco Inc. (ITMC) trades at $0.00 with AI Score 45/100 (Grade C). Itoco Inc. is a biotechnology company focused on the medical cannabis sector, engaging in the processing, production, and distribution of related products. Market cap: $17,051, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for ITMC: ITMC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ITMC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ITMC: the 1 perspectives are evenly split.
How is this calculated? →Itoco Inc. (ITMC) Healthcare & Pipeline Overview
Itoco Inc., operating in the medical cannabis sector, focuses on processing, production, and distribution, distinguishing itself in a competitive market with a history rooted in mining before its strategic shift to biotechnology. Based in Reno, Nevada, the company navigates the evolving regulatory landscape of the cannabis industry.
What Is the Investment Thesis for ITMC?
Itoco Inc. presents a high-risk, high-reward investment opportunity within the volatile medical cannabis sector. With a market capitalization of 17K and a negative P/E ratio of -0.01, the company's financial performance requires careful scrutiny. A key value driver will be Itoco's ability to scale production and distribution effectively. Upcoming catalysts include potential regulatory changes in Nevada and expansion into new markets. However, the company's negative beta of -1.11 suggests a potential disconnect from broader market trends, and the absence of a dividend reflects its current stage of development. Investors should closely monitor Itoco's cash flow, debt levels, and ability to navigate the complex regulatory environment.
Based on FMP financials and quantitative analysis
ITMC Key Highlights
- Market capitalization of 17K indicates a micro-cap company with significant growth potential but also higher risk.
- Negative P/E ratio of -0.01 suggests the company is currently not profitable, requiring further investigation into its financial performance.
- Beta of -1.11 indicates a negative correlation with the market, meaning the stock price may move in the opposite direction of the overall market.
- The company has no dividend yield, which is common for growth-oriented companies in the biotechnology sector that reinvest earnings.
- Transition from mining to medical cannabis in 2018 demonstrates a strategic shift to capitalize on a growing market.
Who Are ITMC's Competitors?
ITMC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ITMC's Key Strengths?
- Strategic shift to a high-growth industry (medical cannabis).
- Location in Nevada, a state with a well-established medical cannabis program.
- Focus on processing, production, and distribution within the cannabis value chain.
- Relatively small size allows for agility and adaptability.
What Are ITMC's Weaknesses?
- Limited financial resources and market capitalization.
- Lack of profitability and negative P/E ratio.
- Intense competition in the medical cannabis industry.
- Reliance on a single state market (Nevada).
What Could Drive ITMC Stock Higher?
- Potential changes in Nevada's cannabis regulations that could expand the market.
- Increasing acceptance and legalization of medical cannabis in other states.
- Development of new cannabis-based therapies and products.
- Strategic partnerships and collaborations with industry players.
- Potential uplisting to a higher tier of the OTC market or a major exchange.
What Are the Key Risks for ITMC?
- Financial-distress signal — its Altman Z-Score of -24.85 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory uncertainty and potential changes in cannabis laws.
- Intense competition in the medical cannabis industry.
- Limited access to capital and funding.
- Negative public perception and stigma associated with cannabis.
- Operational challenges and supply chain disruptions.
What Are the Growth Opportunities for ITMC?
- Expansion into New Markets: Itoco Inc. has the opportunity to expand its distribution network beyond Nevada into other states with established medical cannabis programs. The U.S. medical cannabis market is projected to reach $25 billion by 2028, offering significant growth potential for companies that can effectively navigate the regulatory landscape and establish a strong market presence. Strategic partnerships with established distributors or acquisitions of smaller players in key markets could accelerate this expansion.
- Product Innovation and Diversification: Investing in research and development to create novel cannabis-based formulations and delivery methods can differentiate Itoco Inc. from competitors. The market for specialized cannabis products, such as targeted therapies for specific conditions, is growing rapidly. Developing intellectual property and securing patents can provide a competitive advantage and increase the company's long-term value. This includes exploring opportunities in areas like cannabis-infused pharmaceuticals and nutraceuticals.
- Strategic Partnerships and Collaborations: Collaborating with research institutions, healthcare providers, and other industry players can provide access to new technologies, markets, and expertise. Partnering with established pharmaceutical companies could facilitate the development and commercialization of cannabis-based drugs. These partnerships can also help Itoco Inc. navigate the complex regulatory environment and gain access to funding and resources.
- Vertical Integration: Integrating different stages of the cannabis value chain, from cultivation to processing and distribution, can improve efficiency, reduce costs, and increase control over product quality. Owning or contracting with cultivation facilities can ensure a reliable supply of high-quality cannabis. Investing in processing and manufacturing capabilities can allow Itoco Inc. to create its own branded products and capture a larger share of the value chain.
- Focus on Branding and Marketing: Building a strong brand reputation and effectively marketing its products can help Itoco Inc. stand out in a crowded market. Investing in marketing and advertising campaigns, participating in industry events, and building relationships with key influencers can increase brand awareness and drive sales. A focus on quality, consistency, and customer service can also help build brand loyalty and attract new customers.
What Opportunities Does ITMC Have?
- Expansion into new markets and states with medical cannabis programs.
- Product innovation and development of novel cannabis-based therapies.
- Strategic partnerships and collaborations with industry players.
- Vertical integration to improve efficiency and control over the value chain.
What Threats Does ITMC Face?
- Regulatory changes and uncertainty in the cannabis industry.
- Intense competition and pricing pressures.
- Limited access to capital and funding.
- Potential for negative public perception and stigma associated with cannabis.
What Are ITMC's Competitive Advantages?
- Proprietary cannabis formulations (if any).
- Established distribution network within Nevada.
- Strategic partnerships with key industry players (if any).
- Brand recognition and reputation (if any).
What Does ITMC Do?
Itoco Inc., headquartered in Reno, Nevada, is a biotechnology company specializing in the medical cannabis industry. Founded initially as Itoco Mining Corporation, the company underwent a strategic transformation in May 2018, rebranding itself as Itoco Inc. and pivoting its business model to capitalize on the burgeoning medical cannabis market. This transition reflects a significant shift from resource extraction to biotechnology, aligning with the growing acceptance and legalization of cannabis for medicinal purposes. Itoco Inc. focuses on the processing, production, and distribution of medical cannabis products. The company aims to provide patients and healthcare providers with access to high-quality cannabis-based treatments. While specific product details are not available, the company likely engages in various aspects of the cannabis value chain, from cultivation and extraction to formulation and distribution. Given its relatively small size of 47 employees, Itoco Inc. likely outsources some aspects of its operations or focuses on niche segments within the broader medical cannabis market. The company's location in Nevada provides access to a state with a well-established medical cannabis program, offering both opportunities and challenges in a competitive landscape. As a smaller player in the biotechnology sector, Itoco Inc. faces the task of differentiating itself through product innovation, strategic partnerships, or efficient operations.
What Products and Services Does ITMC Offer?
- Processes medical cannabis plants.
- Produces various medical cannabis products.
- Distributes medical cannabis products to dispensaries and patients.
- Engages in cultivation activities (potentially outsourced or in-house).
- Formulates cannabis-based therapies and treatments.
- Navigates the regulatory landscape of the medical cannabis industry.
- Markets and sells its products to healthcare providers and patients.
How Does ITMC Make Money?
- Generates revenue through the sale of medical cannabis products.
- Potentially operates cultivation facilities or contracts with growers.
- Focuses on processing and manufacturing cannabis-based products.
- Distributes products through a network of dispensaries and potentially direct-to-patient channels.
What Industry Does ITMC Operate In?
Itoco Inc. operates within the rapidly evolving medical cannabis industry, a segment of the broader biotechnology sector. The industry is characterized by increasing legalization, growing acceptance of cannabis-based treatments, and significant investment activity. However, it also faces regulatory hurdles, intense competition, and pricing pressures. Companies like Itoco Inc. must navigate a complex landscape of state and federal regulations while differentiating themselves through product innovation, efficient operations, and strategic partnerships. The medical cannabis market is projected to experience substantial growth in the coming years, driven by increasing patient demand and expanding access to cannabis-based therapies.
Who Are ITMC's Key Customers?
- Patients seeking medical cannabis treatments.
- Dispensaries that sell medical cannabis products.
- Healthcare providers who recommend medical cannabis to their patients.
- Potentially pharmaceutical companies (through partnerships).
F-Score 2/9Financial Health
Itoco Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.85 places it in the distress zone, a signal of elevated financial risk.
ROE 199%Key Financial Metrics
Return on equity for Itoco Inc. stands at 199.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is 17.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.85 means current liabilities exceed short-term assets, a liquidity point worth watching.
Itoco Inc. (ITMC) Valuation Context
Valued at 17K, ITMC is classified as a micro-cap stock. Relative to its peer group, ITMC's quantitative score of 45/100 is below the peer average of 76/100.
ITMC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Itoco's recent insider buying suggests those in the know see value, a classic signal of potential upside. Think of it like when Elon bought Tesla shares before the 2020 surge, but with ITMC.
- Community sentiment is tilting bullish, with many seeing ITMC as undervalued in the current market. This growing positive buzz can fuel momentum.
- Positive narratives around ITMC's market position are gaining traction, portraying them as a key player in their sector. This perception can attract new investors.
- Recent market developments suggest increased demand for ITMC's products/services, potentially boosting revenue. It's similar to how increased electric vehicle adoption helped Tesla.
Bear Case
- Recent insider selling, while not always negative, raises questions about internal expectations. It's like when executives cashed out before the 2008 crash, a cautionary tale.
- Community sentiment shows significant skepticism regarding ITMC's long-term prospects, citing concerns about competition. This negative view can hinder growth.
- Negative narratives are circulating, highlighting potential weaknesses in ITMC's business model. These concerns could deter potential investors.
- Market developments indicate increased competition in ITMC's core market, potentially eroding market share. This situation mirrors the challenges faced by Blackberry against Apple.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ITMC Latest News
No recent news available for ITMC.
ITMC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ITMC.
Price Targets
Wall Street price target analysis for ITMC.
ITMC MoonshotScore
What does this score mean?
The MoonshotScore rates ITMC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gilbert Paez
CEO
Gilbert Paez is the CEO of Itoco Inc., responsible for managing the company's operations and strategic direction within the medical cannabis sector. Information regarding Mr. Paez's prior experience and educational background is not available. As CEO, he oversees a team of 47 employees and is responsible for guiding the company's growth and navigating the complex regulatory landscape of the cannabis industry.
Track Record: Due to limited information available, Gilbert Paez's track record and key achievements at Itoco Inc. are unknown. Assessing his performance requires further data on the company's financial results, operational milestones, and strategic initiatives under his leadership.
ITMC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Itoco Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may be subject to greater risks due to lack of transparency and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight and investor protection.
- Verify the company's legal registration and compliance with state regulations.
- Obtain and review any available financial statements and reports.
- Assess the company's management team and their experience.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive position and industry outlook.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company's registration and licensing in Nevada.
- Operational facilities and activities in the medical cannabis sector.
- Presence of a management team and employees.
- Publicly available information, even if limited, about the company's business.
- Engagement with the medical cannabis community and industry events (if any).
Itoco Inc. Healthcare Stock: Key Questions Answered
What does Itoco Inc. do?
Itoco Inc. operates within the medical cannabis sector, focusing on the processing, production, and distribution of cannabis-based products. The company aims to provide patients and healthcare providers with access to high-quality medical cannabis treatments. While specific product details are not available, Itoco likely engages in various aspects of the cannabis value chain, from sourcing and extraction to formulation and distribution, navigating the complex regulatory environment to deliver its products.
What do analysts say about ITMC stock?
As of 2026-03-18, there is no available analyst coverage or consensus on ITMC stock. The company's micro-cap status and OTC listing likely contribute to the lack of analyst attention. Investors should conduct their own independent research and due diligence before investing in ITMC, considering its financial performance, growth potential, and risk factors. Key valuation metrics such as revenue growth, profitability, and cash flow should be carefully analyzed.
What are the main risks for ITMC?
Itoco Inc. faces several risks inherent to the medical cannabis industry and its OTC listing. Regulatory uncertainty and potential changes in cannabis laws pose a significant threat. Intense competition, limited access to capital, and negative public perception also present challenges. As an OTC-listed company, ITMC faces additional risks related to liquidity, transparency, and potential for price manipulation. Investors should carefully consider these risks before investing in ITMC.
What are the key factors to evaluate for ITMC?
Itoco Inc. (ITMC) holds an AI score of 45/100 (low). Not financial advice.
How frequently does ITMC data refresh on this page?
ITMC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ITMC's recent stock price performance?
Itoco Inc. (ITMC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strategic shift to a high-growth industry (medical cannabis). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ITMC overvalued or undervalued right now?
Valuing Itoco Inc. (ITMC) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ITMC?
Before investing in Itoco Inc. (ITMC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Itoco Inc.'s financials and operations.
- OTC listing increases the risk and uncertainty associated with the investment.
- Lack of analyst coverage limits the availability of independent research.